DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care
DocGo (NASDAQ: DCGO) has expanded its partnership with SHL Telemedicine to integrate SmartHeart® portable 12-lead ECG devices across its mobile health care units nationwide, following initial deployment in the New York-New Jersey area. The collaboration aims to address the critical gap in cardiovascular care access, noting that 46% of U.S. counties lack cardiologists according to the Journal of the American College of Cardiology.
The partnership will enable high-quality ECG screenings in patients' homes and underserved communities, with cardiologist-reviewed results available promptly. The first phase of expansion will target California, focusing on rural communities and healthcare deserts. This initiative aims to improve patient outcomes while reducing emergency room visits and overall healthcare costs.
DocGo (NASDAQ: DCGO) ha ampliato la sua partnership con SHL Telemedicine per integrare dispositivi ECG portatili SmartHeart® a 12 derivazioni in tutte le sue unità sanitarie mobili a livello nazionale, dopo il primo deployment nell'area di New York-New Jersey. Questa collaborazione mira a colmare il critico divario nell'accesso alle cure cardiovascolari, evidenziando come il 46% delle contee americane sia privo di cardiologi, secondo quanto riportato dal Journal of the American College of Cardiology.
La partnership permetterà screening ECG di alta qualità nelle case dei pazienti e nelle comunità svantaggiate, con risultati esaminati da cardiologi disponibili rapidamente. La prima fase di espansione si concentrerà sulla California, focalizzandosi sulle comunità rurali e sui deserti sanitari. Questa iniziativa mira a migliorare i risultati per i pazienti riducendo nel contempo le visite al pronto soccorso e i costi complessivi delle cure sanitarie.
DocGo (NASDAQ: DCGO) ha ampliado su asociación con SHL Telemedicine para integrar dispositivos ECG portátiles SmartHeart® de 12 derivaciones en todas sus unidades de atención médica móvil a nivel nacional, tras el despliegue inicial en el área de Nueva York-Nueva Jersey. La colaboración busca abordar la brecha crítica en el acceso a la atención cardiovascular, señalando que el 46% de los condados de EE. UU. carecen de cardiólogos, de acuerdo con el Journal of the American College of Cardiology.
La asociación permitirá realizar pruebas de ECG de alta calidad en los hogares de los pacientes y en comunidades desatendidas, con resultados revisados por cardiólogos disponibles de manera rápida. La primera fase de expansión se centrarán en California, enfocándose en comunidades rurales y desiertos de atención sanitaria. Esta iniciativa tiene como objetivo mejorar los resultados para los pacientes, a la vez que reduce las visitas a la sala de emergencias y los costos generales de atención médica.
DocGo (NASDAQ: DCGO)는 SHL Telemedicine와의 파트너십을 확대하여, 뉴욕-뉴저지 지역에서 처음 배포된 이후로 전국의 모바일 의료 유닛에 SmartHeart® 이동식 12 유도 ECG 기기를 통합합니다. 이 협업은 심혈관 치료 접근성의 심각한 격차를 해결하고자 하며, 미국의 46% 카운티에 심장 전문의가 부족하다는 점을 지적합니다, 이는 미국심장병학회 저널에 따른 것입니다.
이번 파트너십은 환자의 가정과 의료 서비스가 부족한 지역에서 고품질 ECG 검사를 가능하게 하며, 심장 전문의가 검토한 결과를 신속하게 제공받을 수 있습니다. 확장의 첫 단계는 캘리포니아를 목표로 하며, 농촌 지역과 의료 서비스가 부족한 지역에 중점을 둘 것입니다. 이 이니셔티브는 환자 결과를 개선하고 응급실 방문 및 전체 의료 비용을 줄이는 것을 목표로 하고 있습니다.
DocGo (NASDAQ: DCGO) a élargi son partenariat avec SHL Telemedicine pour intégrer des dispositifs ECG portables SmartHeart® à 12 dérivations dans toutes ses unités de soins mobiles à l'échelle nationale, suite à un déploiement initial dans la région de New York-New Jersey. Cette collaboration vise à combler l'écart critique dans l'accès aux soins cardiovasculaires, en notant que 46 % des comtés américains manquent de cardiologues, selon le Journal of the American College of Cardiology.
Le partenariat permettra des dépistages ECG de haute qualité dans les foyers des patients et dans les communautés mal desservies, avec des résultats examinés par des cardiologues disponibles rapidement. La première phase d'expansion ciblera la Californie, en mettant l'accent sur les communautés rurales et les déserts de soins de santé. Cette initiative vise à améliorer les résultats des patients tout en réduisant les visites aux urgences et les coûts globaux des soins de santé.
DocGo (NASDAQ: DCGO) hat seine Partnerschaft mit SHL Telemedicine erweitert, um SmartHeart® tragbare 12-Kanal-EKG-Geräte in seinen mobilen Gesundheitseinheiten im ganzen Land zu integrieren, nachdem eine erste Bereitstellung im Raum New York-New Jersey erfolgte. Die Zusammenarbeit zielt darauf ab, die kritische Lücke im Zugang zur kardiovaskulären Versorgung zu schließen und weist darauf hin, dass 46 % der US-Landkreise keine Kardiologen haben, so das Journal of the American College of Cardiology.
Die Partnerschaft ermöglicht qualitativ hochwertige EKG-Screenings in den Haushalten der Patienten und in unterversorgten Gemeinschaften, wobei die von Kardiologen geprüften Ergebnisse zeitnah zur Verfügung stehen. Die erste Phase der Expansion wird Kalifornien anvisieren und sich auf ländliche Gemeinschaften und Gesundheitsdeserts konzentrieren. Diese Initiative zielt darauf ab, die Ergebnisse für Patienten zu verbessern und gleichzeitig die Notaufbesuche und die Gesamtkosten der medizinischen Versorgung zu senken.
- Expansion of service coverage beyond NY-NJ area to nationwide markets
- Addresses significant market gap with 46% of U.S. counties lacking cardiologists
- Potential reduction in healthcare costs through prevention of emergency room visits
- Strategic entry into California market targeting underserved areas
- None.
Insights
This partnership marks a significant advancement in mobile healthcare delivery, combining DocGo's established mobile health infrastructure with SHL's SmartHeart® technology. The integration addresses a critical market gap, targeting the 46% of U.S. counties lacking cardiologists. The expansion from NY-NJ to California represents a strategic move into a large, underserved market.
The partnership's value proposition centers on transforming accessibility to specialized cardiac care while potentially reducing healthcare costs through preventive diagnostics and early intervention. This aligns with the broader industry shift toward decentralized healthcare delivery and value-based care models. The technology integration could drive revenue growth through increased service offerings and market expansion, while improving operational efficiency in cardiac diagnostics.
This expansion strengthens DocGo's competitive position in the mobile healthcare market by addressing a significant service gap in cardiovascular care. The California expansion is particularly notable, as it's one of the largest healthcare markets in the U.S. The partnership enhances DocGo's service portfolio and could drive market share growth in the mobile health sector.
The focus on underserved communities and healthcare deserts presents substantial growth opportunities, especially given the increasing demand for accessible healthcare solutions. This strategic move could positively impact DocGo's revenue streams and market valuation, particularly as healthcare accessibility continues to be a priority in public health policy.
According to the Journal of the American College of Cardiology,
“This partnership transforms homes and mobile health units into cutting-edge diagnostic hubs, empowering patients with convenient, high-quality care wherever they are,” said Lee Bienstock, CEO of DocGo. “Incorporating SmartHeart® into home visits helps reduce barriers to cardiovascular care, while enabling early intervention and preventing costly emergency room visits.”
The partnership expansion also represents DocGo’s continued innovation in delivering scalable, patient-centric healthcare solutions that help improve outcomes while lowering overall costs.
“We are proud to extend our partnership with DocGo to provide accessible, high-quality cardiovascular diagnostics that help patients achieve better health outcomes while addressing the nation’s pressing need for equitable healthcare access,” said David Arnon, CEO of SHL Telemedicine.
The first phase of this partnership expansion will focus on
About DocGo
DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo's proprietary technology and relationships with a dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient’s home or workplace. Together with DocGo’s integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com. To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visit www.proactivecarenow.com.
About SHL Telemedicine
SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users who use SmartHeart for personal use and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200). For more information, please visit our website at www.shl-telemedicine.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the Company’s plans, strategies, outcomes, and prospects, both business and financial, including the Company’s expanded partnership with SHL Telemedicine, the expected benefits of such partnership and the expected benefits of SmartHeart® devices. These statements are based on the beliefs and assumptions of the Company’s management. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions, outcomes, results or expectations. Accordingly, you should not place undue reliance on such statements. All statements other than statements of historical fact are forward-looking. In some cases, these statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “might,” “will,” “should,” “could,” “can,” “would,” “design,” “potential,” “seeks,” “plans,” “scheduled,” “anticipates,” “intends” or the negative of these terms or similar expressions. Forward-looking statements are inherently subject to substantial risks, uncertainties and assumptions, many of which are beyond the Company’s control, and which may cause the Company’s actual results or outcomes, or the timing of results or outcomes, to differ materially from those contained in the Company’s forward-looking statements, including, but not limited to the following: the Company’s ability to successfully implement its business strategy, including with respect to its partnership with SHL Telemedicine and the use of SmartHeart® devices; the Company’s reliance on and ability to maintain its contractual relationships with its healthcare provider partners and clients; the Company’s ability to compete effectively in a highly competitive industry; the Company’s ability to maintain existing contracts; the Company’s reliance on government contracts; the Company’s ability to effectively manage its growth; the Company’s financial performance and future prospects; the Company’s ability to deliver on its business strategies or models, plans and goals; the Company’s ability to expand geographically; the Company’s competitive position and opportunities, including its ability to realize the benefits from its operating model; and other risk factors included in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements made in this press release are based on events or circumstances as of the date on which the statements are made. The Company undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as and to the extent required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241218295511/en/
Media:
Tommy Meara
Moxie Strategies
718-309-3506
tommy@moxiestrategies.com
Investors:
Mike Cole
DocGo
949-444-1341
mike.cole@docgo.com
ir@docgo.com
Source: DocGo Inc.
FAQ
What is the impact of DocGo's (DCGO) partnership with SHL Telemedicine on healthcare accessibility?
Which markets will DocGo (DCGO) expand its SmartHeart ECG services to in 2024?
How does DocGo's (DCGO) SmartHeart partnership reduce healthcare costs?
What technology is DocGo (DCGO) implementing in its mobile health units?
